Aphios Announces Collaboration With Japanese Companies For Development Of Orally-Bioavailable Anti-Cancer Therapeutic
10/19/2005 5:11:39 PM
WOBURN, Mass.--(BUSINESS WIRE)--July 19, 2005--Aphios Corporation today announced that it has entered a Research and Development collaboration with two Japanese companies, Bio Research Corporation of Yokohama, Yokohama, Japan and Tokyo Supply, Ltd., Minato, Japan to develop an orally-bioavailble anti-cancer therapaeutic.
The collaborators plan to develop a water-soluble paclitaxel prodrug. The molecule is a combination of a paclitaxel molecule, the potent anticancer drug, and a sugar molecule that enhances solubility. This molecular combination is not bioactive prior to treatment and is significantly more water-soluble than paclitaxel. The water-soluble nature of this novel therapeutic allows for oral digestion rather than intra-venous (IV) injection. After ingestion and adsorption in the gut, serum enzymes break the combined molecule down into the bioactive paclitaxel and a sugar molecule. Preclinical testing (both in in vitro cell culture experiments and in vivo animal studies) indicates that the paclitaxel prodrug is superior to paclitaxel (Taxol(R)) and equivalent to docetaxel (Taxotere(R)) in therapeutic efficacy. This paclitaxel prodrug has been patented in the United States and Japan.
comments powered by